Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLN | Q9BYT8 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 3/20 | 0.47 |
| ▸ | MC3R | P41968 | 3/20 | 0.47 |
| ▸ | MC5R | P33032 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | MC1R | Q01726 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125551 | 1.00 | NLN (0.50) | NLNDPP4MC4RMC3RMC5R | |
| SCHEMBL5558741 | 0.86 | CA12 (0.52) | NLNDPP4MC4RMC3RMC5R | |
| SCHEMBL17337848 | 0.85 | ALPI (0.54) | — | |
| SCHEMBL1769595 | 0.85 | NLN (0.50) | NLNDPP4OPRD1 | |
| SCHEMBL12520303 | 0.85 | NLN (0.50) | NLNDPP4OPRD1 | |
| SCHEMBL1769590 | 0.85 | NLN (0.50) | NLNDPP4OPRD1 | |
| SCHEMBL4634385 | 0.84 | NLN (0.49) | NLNDPP4MC4RMC3RMC5R | |
| SCHEMBL30104067 | 0.83 | OPRD1 (0.54) | NLNDPP4MC4RMC3RMC5R | |
| SCHEMBL5556817 | 0.83 | NLN (0.62) | NLNDPP4MC4RMC3RMC5R | |
| SCHEMBL6020723 | 0.81 | NLN (0.52) | NLNDPP4OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-7279573-B2 | Amide derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-20060142264-A1 | Novel amide derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| US-7064121-B2 | N-acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20050059699-A1 | N-acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2005-03-17 | — | — | US | disclosed |
| US-6864250-B1 | N-acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2005-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142264-A1 | Novel amide derivatives | GHRHR, GHSR, SSTR3 | NLN 1155/4885DPP4 578/4885MC4R 95/4885 |
| US-20050059699-A1 | N-acylated lipophilic amino acid derivatives | GHRHR, NPPA, SSTR5 | NLN 558/4885DPP4 689/4885MC4R 165/4885 |
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | GHRHR, NPPA, SSTR5 | NLN 558/4885DPP4 689/4885MC4R 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.